EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024)

Kana Morihisa iD, Hiroyuki Yoshitsugu, Hirokazu Wakuda iD, Naoto Uemura iD

Clinical and Translational Science · 2026-06 · 19 (6)

DOI: 10.1111/cts.70626 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 15.06.2026. Verfasst von Kana Morihisa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine, Yufu City, Oita Prefecture, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Drug Development, Healthy Volunteers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticancer agents with favorable safety profiles, such as immunomodulators and molecular‐targeted agents, are increasingly used in recent cancer therapy, and clinical trials for these agents increasingly incorporate healthy volunteers as well as cancer patients. Clinical trials in healthy volunteers allow intensive safety monitoring and intensive pharmacokinetic sampling, enabling the acquisition of high‐quality, broad‐range pharmacokinetic and safety data within a shorter timeframe and at lower cost. Leveraging these advantages by utilizing healthy volunteer trials in place of patient trials may contribute to more rapid and efficient implementation of anticancer drug development and is expected to help eliminate the “drug lag” and “drug loss” that have been concerns in Japan's research and development process in recent years. In this study, we investigated the clinical data packages of newly approved anticancer agents in Japan from April 2014 to March 2024 and evaluated trends in cases in which data from Japanese healthy volunteers were obtained. We then summarized key considerations for anticancer drug development in Japan regarding whether data from Japanese healthy volunteers should be obtained.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsDrug DevelopmentHealthy VolunteersHumansJapanDrug ApprovalClinical Trials as Topic

Stichwörter der Autor:innen

drug developmenthealthy subjectsoncology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine, Yufu City, Oita Prefecture, Japan.
  • General Clinical Research Center, Oita University Hospital, Yufu City, Oita Prefecture, Japan.

ORCID-Profile: Kana Morihisa, Hirokazu Wakuda, Naoto Uemura

Zitieren

APA

Morihisa, K., Yoshitsugu, H., Wakuda, H., & Uemura, N. (2026). Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024). Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70626

Vancouver

Morihisa K, Yoshitsugu H, Wakuda H, Uemura N. Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024). Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70626

BibTeX
@article{Morihisa2026,
  author = {Morihisa, Kana and Yoshitsugu, Hiroyuki and Wakuda, Hirokazu and Uemura, Naoto},
  title = {Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024)},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1111/cts.70626}
}
Kostenlos starten →